CYP2C19 Genotyping for Clopidogrel/Plavix, Clopidogrel (Plavix), Cytochrome P450 2C19 Genotyping, Plavix (Clopidogrel), Treatment Resistant Depression Panel, Plavix Inhibition
ARUP #3001508, EPIC: LAB7036, SOFT: XYP19
Specimen Collection Criteria
Collect: One Lavender-top EDTA tube. (Minimum: 1.0 mL)
Also acceptable: One Yellow-top ACD tube.
Physician Office/Draw Specimen Preparation
Do not centrifuge. Maintain whole blood refrigerated (2-8°C or 36-46°F) prior to transport.
Preparation for Courier Transport
Transport: Whole blood refrigerated (2-8°C or 36-46°F). Minimum: 1.0 mL)
Specimens not collected and processed as indicated.
This test will only be performed once in a lifetime for a patient.
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 1 week
Frozen (-20°C/-4°F or below): 1 month
Specimen Storage in Department Prior to Disposal:
Extracted DNA may be available for additional testing if clinically indicated.
Specimen retention time is determined by the policy of the reference laboratory. Contact the Sendout Laboratory with any questions.
Sent to ARUP Laboratories, Salt Lake City, UT.
Results available in 6-11 business days.
Polymerase Chain Reaction (PCR)/ Fluorescence.
This test detects by report (normal) allele CYP2C19*1, and the following mutant alleles: *2 → *10, *13, and *17.
- Based on the CYP2C19 genotype, patients may be classified as extensive, intermediate, poor, or ultrarapid metabolizers of Clopidogrel. Drug dose selection based on genotype is the basis of individualized therapy.
- Testing is recommended on patients to be started on Plavix (Clopidogrel) therapy.
LOINC: 31208-2, 57132-3, 50398-7
Send Outs Laboratory – RO
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.